The PROTAC ARV-471, developed by Arvinas and Pfizer, is being evaluated in phase I/II trials in breast cancer as an oral ER degrader, and preclinical efforts to target HER2 have been effective in degrading HER2 to slow tumor growth (97). Here, ESR1 is linked to breast carcinoma.